• español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UVaDOCCommunitiesBy Issue DateAuthorsSubjectsTitles

    My Account

    Login

    Statistics

    View Usage Statistics

    Share

    View Item 
    •   UVaDOC Home
    • SCIENTIFIC PRODUCTION
    • Departamentos
    • Dpto. Anatomia y Radiología
    • DEP04 - Artículos de revista
    • View Item
    •   UVaDOC Home
    • SCIENTIFIC PRODUCTION
    • Departamentos
    • Dpto. Anatomia y Radiología
    • DEP04 - Artículos de revista
    • View Item
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano

    Export

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/57728

    Título
    Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
    Otros títulos
    Immunomodulator drugs for the treatment of multiple myeloma
    Autor
    Fernández Lázaro, DiegoAutoridad UVA
    Fernandez Lazaro, César
    Caballero García, AlbertoAutoridad UVA
    Córdova Martínez, AlfredoAutoridad UVA Orcid
    Año del Documento
    2018
    Editorial
    Sociedad Médica de Santiago
    Descripción
    Producción Científica
    Documento Fuente
    Revista médica de Chile, 2018; Vol. 146, Nª 12, págs. 1444-1451
    Abstract
    Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immunomodulatory (IMiDs) compounds are structural and functional analogs of thalidomide, which were designed to improve the immunomodulatory and anticancer properties and tolerability profiles. We review the development of second generation IMiDs, lenalidomide and pomalidomide, their immunomodulatory and tumoricidal effects, their mechanisms of action, as well as the influence of dexamethasone on their effect and pharmacological resistance. In conclusion, lenalidomide and pomalidomide demonstrate a powerful activity and they are highly effective and well-tolerated treatment options for patients with myeloma, used alone or in combination with dexamethasone.
    Materias (normalizadas)
    Multiple myeloma - Treatment
    Multiple myeloma - Diagnosis
    Immunology
    Materias Unesco
    3207.13 Oncología
    3207.08 Hematología
    Palabras Clave
    Dexamethasone
    Neoplasm
    ISSN
    0034-9887
    Revisión por pares
    SI
    DOI
    10.4067/s0034-98872018001201444
    Version del Editor
    https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018001201444
    Propietario de los Derechos
    © Sociedad Médica de Santiago
    Idioma
    spa
    URI
    https://uvadoc.uva.es/handle/10324/57728
    Tipo de versión
    info:eu-repo/semantics/publishedVersion
    Derechos
    openAccess
    Collections
    • DEP04 - Artículos de revista [31]
    Show full item record
    Files in this item
    Nombre:
    Agentes-inmunomoduladores-IMiDs.pdf
    Tamaño:
    184.9Kb
    Formato:
    Adobe PDF
    Thumbnail
    FilesOpen
    Atribución 4.0 InternacionalExcept where otherwise noted, this item's license is described as Atribución 4.0 Internacional

    Comentarios

    Universidad de Valladolid

    Powered by MIT's. DSpace software, Version 5.10